JP2024523429A5 - - Google Patents

Info

Publication number
JP2024523429A5
JP2024523429A5 JP2023578116A JP2023578116A JP2024523429A5 JP 2024523429 A5 JP2024523429 A5 JP 2024523429A5 JP 2023578116 A JP2023578116 A JP 2023578116A JP 2023578116 A JP2023578116 A JP 2023578116A JP 2024523429 A5 JP2024523429 A5 JP 2024523429A5
Authority
JP
Japan
Prior art keywords
composition according
virus
viral infection
alkyl
neurological complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523429A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/066548 external-priority patent/WO2022263624A1/en
Publication of JP2024523429A publication Critical patent/JP2024523429A/ja
Publication of JP2024523429A5 publication Critical patent/JP2024523429A5/ja
Pending legal-status Critical Current

Links

JP2023578116A 2021-06-18 2022-06-17 ウイルス感染の神経学的合併症の処置と予防のための新規化合物 Pending JP2024523429A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21180462.0 2021-06-18
EP21180462 2021-06-18
PCT/EP2022/066548 WO2022263624A1 (en) 2021-06-18 2022-06-17 Novel compounds for the treatment and prevention of neurological complications of viral infections

Publications (2)

Publication Number Publication Date
JP2024523429A JP2024523429A (ja) 2024-06-28
JP2024523429A5 true JP2024523429A5 (cg-RX-API-DMAC7.html) 2025-06-23

Family

ID=76532115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578116A Pending JP2024523429A (ja) 2021-06-18 2022-06-17 ウイルス感染の神経学的合併症の処置と予防のための新規化合物

Country Status (6)

Country Link
US (1) US20240307339A1 (cg-RX-API-DMAC7.html)
EP (1) EP4355316A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024523429A (cg-RX-API-DMAC7.html)
KR (1) KR20240022560A (cg-RX-API-DMAC7.html)
CN (1) CN117529311A (cg-RX-API-DMAC7.html)
WO (1) WO2022263624A1 (cg-RX-API-DMAC7.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150125A (en) * 1977-09-30 1979-04-17 Abbott Laboratories Triglyceride ester of phosphonoacetic acid having antiviral activity
JP2000007581A (ja) * 1998-06-18 2000-01-11 Nippon Kayaku Co Ltd 抗ウイルススプレー剤
KR20120129898A (ko) * 2009-12-30 2012-11-28 베일러 리서치 인스티튜트 알츠하이머 질환 및 노화 뇌를 위한 보충대사 치료요법
CN104940589A (zh) * 2015-06-18 2015-09-30 王峰 治疗急性结膜炎的中药制剂及制法
NZ749389A (en) * 2016-06-08 2022-12-23 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
WO2018159941A1 (ko) * 2017-03-02 2018-09-07 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
KR101991661B1 (ko) * 2017-03-02 2019-06-21 대화제약 주식회사 자나미비르를 포함하는 안정한 약제학적 조성물
WO2019052629A1 (en) * 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT

Similar Documents

Publication Publication Date Title
O’Brien et al. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy
Chou et al. Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications
De Clercq et al. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections
D Vadlapudi et al. Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents
JP2021080269A5 (cg-RX-API-DMAC7.html)
JP6862366B2 (ja) 眼のウイルス感染症の治療のための医薬品
Sekizawa et al. Encephalitis resulting from reactivation of latent herpes simplex virus in mice
JP2024520132A5 (cg-RX-API-DMAC7.html)
US9840525B2 (en) Crystal form of tenofovir prodrug, preparation method thereof, and method of use thereof
US12454540B2 (en) Prodrugs of L-BHDU and methods of treating viral infections
JP2002540146A5 (cg-RX-API-DMAC7.html)
JP2007530703A5 (cg-RX-API-DMAC7.html)
JP2015515496A5 (cg-RX-API-DMAC7.html)
CA2548608A1 (en) Anhydrous crystalline form of valacyclovir hydrochloride
US20030144235A1 (en) 4'-thio-L-xylofuranosyl nucleosides, precursors thereof, preparation and use thereof
WO2003101456A1 (de) Verwendung von cgmp stimulierenden verbindungen
KR960704464A (ko) 포유동물 세포에서의 뉴클레오사이드와 뉴클레오베이스 수송억제 방법 및 바이러스 복제억제 방법(method for inhibiting nucleoside and nucleoside transport and virus replication in mammalian cells)
Beadle et al. Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: efficacy against HSV-1 infection in mice
CN106794363A (zh) 在单一丸剂/片剂/胶囊中米诺环素、氟康唑和阿托伐他汀在治疗多发性硬化中的用途
Higaki et al. Effect of oral valaciclovir on herpetic keratitis
US20140364407A1 (en) Medical or therapeutic application of a composite material of ruthenium with a nitrosyl ligand
Licastro Exogenous and Endogenous Virus Infection and Pollutants Drive Neuronal Cell Senescence and Alzheimer's Disease.
JP2024522820A5 (cg-RX-API-DMAC7.html)
Shiota Clinical evaluation of acyclovir in the treatment of ulcerative herpetic keratitis
JENSEN et al. Acyclovir in the treatment of herpetic keratitis